Fiscal Year 2020 Department of Defense Amyotrophic Lateral Sclerosis Research Program Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
 Therapeutic Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-20-ALSRP-TDA 	Independent investigators at all levels	 Pre-Application is required; Full Application submission is by invitation only Supports preclinical secondary validation and IND-enabling studies of therapeutics for ALS. Preliminary data are required, including efficacy in at least one ALS-relevant model system with a lead molecule/class of compounds. Biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the TDA proposal. 	 Maximum funding of \$1.0 million for direct costs (plus indirect costs) Maximum period of performance is 3 years 	 Pre-Application: April 15, 2020 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Application: July 30, 2020 11:59 p.m. Eastern Time
Therapeutic Idea Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-20-ALSRP-TIA	Independent investigators at all levels	 Pre-Application is required; Full Application submission is by invitation only Supports hypothesis-driven preclinical therapeutic development. Preliminary data are not required. Projects focusing primarily on investigating ALS pathophysiology are outside the scope of this award mechanism. Early Career Investigators are encouraged to apply. Therapeutic Relevant Biomarker Option: Applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the Funding Opportunity Announcement, will qualify for a higher level of funding. 	 Maximum funding of \$500,000 for direct costs (plus indirect costs) Maximum funding of \$600,000 for direct costs plus indirect costs if applying for the Therapeutic Relevant Biomarker Option Maximum period of performance is 2 years 	 Pre-Application: April 15, 2020 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Application: July 30, 2020 11:59 p.m. Eastern Time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
Clinical Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-20-ALSRP-CDA	Independent investigators at all levels	 Pre-application is required; full application submission is by invitation only. Supports leveraging of human-based ALS resources through correlative clinical research. Early Career Investigators and/or Early Career Physician Scientists are encouraged to apply. Types of efforts that will be supported include: Using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes Adding a companion aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial Studies to evaluate optimizing components of current ALS clinical care 	 Maximum funding of \$300,000 for direct costs (plus indirect costs) Maximum period of performance is 2 years 	 Pre-Application: April 15, 2020 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Application: July 30, 2020 11:59 p.m. Eastern Time